Inovio Pharmaceuticals Q2 2024 GAAP EPS $(1.19) Misses $(1.10) Estimate, Sales $100.762K Miss $121.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Inovio Pharmaceuticals (NASDAQ:INO) reported Q2 2024 GAAP EPS of $(1.19), missing the $(1.10) estimate by 8.18%. Sales were $100.762K, missing the $121.500K estimate by 17.07%, and down 55.41% from the same period last year.
August 08, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inovio Pharmaceuticals reported Q2 2024 GAAP EPS of $(1.19), missing the $(1.10) estimate by 8.18%. Sales were $100.762K, missing the $121.500K estimate by 17.07%, and down 55.41% from the same period last year.
The significant miss on both EPS and sales estimates, along with a substantial year-over-year decline in sales, is likely to negatively impact Inovio Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100